19.When the above judgments are applied to the facts of the present case, it is seen that the shelf life of the drug was up to February 2022 and it is evident from the analysis report submitted by the Government Analyst. Hence this right is available till the shelf life of the drug is available. The petitioners expressed their mind that they want to challenge the report of the Government Analyst and they wanted the sample to be sent for further analysis. Admittedly, the respondent did not send the sample for further analysis. However, the respondent had sent the third portion sample to the petitioners as early as on 25.06.2018. When this sample was received by the petitioners, it ought to have been sent to the Central Government Laboratory, instead the petitioner had chosen to send it to some private Laboratory. Even thereafter, after the summons was served on the petitioners in the private complaint, in the year 2019, the petitioners had an opportunity to send the sample for further analysis by making a request before the Court as provided under Section 25(4) of the Act. The petitioners did not choose this option also. The quash petition was filed before this Court on that ground. Thus, it is quite apparent that for the period from 2018 to February 2022, the petitioners had the opportunity to send the sample for analysis to the Central Government Laboratory and for reasons best known to the petitioners, it was not sent. Just because, the respondent